文献速递外周动脉疾病

慢性肢体威胁性缺血术后双联抗血小板与单药治疗的比较:系统综述与荟萃分析

Dual antiplatelet therapy versus monotherapy after surgical intervention for chronic limb-threatening ischemia: Systematic review and meta-analysis with endovascular subanalysis.
PubMed 文献 · J Vasc Surg · 2025-08-06

该系统综述与荟萃分析纳入7项研究共53,907例慢性肢体威胁性缺血患者,比较双联抗血小板治疗(DAPT)与单药抗血小板治疗(MAPT)的安全性和有效性。DAPT与主要截肢风险显著降低相关,但增加主要不良肢体事件和任何血管再干预风险,死亡率、大出血、无截肢生存率无显著差异。

要点

  • DAPT与主要截肢风险显著降低相关(RR 0.82,95%CI 0.75-0.89)。
  • DAPT增加主要不良肢体事件(RR 1.10,95%CI 1.03-1.18)和任何血管再干预风险(RR 1.07,95%CI 1.03-1.10)。
  • 死亡率、大出血、无截肢生存率及靶病变再干预在DAPT与MAPT间无显著差异。

核心结论

  • DAPT可能降低慢性肢体威胁性缺血患者的主要截肢风险,但可能增加主要不良肢体事件和任何血管再干预的风险。

研究设计与样本

  • 系统综述与荟萃分析,纳入7项研究(6项观察性研究和1项随机对照试验),共53,907例患者。
  • 检索Medline、Embase和Cochrane数据库,并进行血管内手术亚组分析。
  • 使用RStudio软件进行统计分析,采用I2统计量评估研究异质性。

主要发现

  • DAPT与主要截肢风险显著降低相关(RR 0.82;95%CI 0.75-0.89;P < .001;I2 = 0%)。
  • 血管内手术亚组分析中DAPT同样与主要截肢风险降低相关(RR 0.83;95%CI 0.73-0.93;P = .002;I2 = 0%)。
  • DAPT与主要不良肢体事件风险增加相关(RR 1.10;95%CI 1.03-1.18;P = .007)。
  • DAPT与任何血管再干预风险增加相关(RR 1.07;95%CI 1.03-1.10;P < .001;I2 = 0%)。
  • 总体和血管内分析中,DAPT与MAPT在死亡率、大出血、靶病变再干预或无截肢生存率方面均无显著差异。

临床怎么用

  • 对于慢性肢体威胁性缺血术后患者,DAPT可考虑用于降低截肢风险,但需权衡主要不良肢体事件和再干预风险增加。

局限性

  • 纳入研究以观察性研究为主(6项观察性研究和1项随机对照试验),可能存在混杂偏倚。
  • 三项研究使用同一注册数据库但未纳入同一分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We compared the safety and efficacy of dual antiplatelet therapy (DAPT) vs monoantiplatelet therapy (MAPT) in patients with chronic limb-threatening ischemia undergoing open and/or endovascular surgery. METHODS: Article screening was conducted using Medline, Embase, and the Cochrane databases. The outcomes analyzed included major bleeding, major amputation, major adverse limb events, amputation-free survival, reintervention, and mortality. A subanalysis was performed, which included only patients who underwent endovascular surgery. Additionally, a subgroup analysis was conducted to differentiate between target lesion reinterventions and interventions in other vessels. Statistical analysis was performed using the RStudio software. Study heterogeneity was assessed using the I2 statistic. RESULTS: Seven studies with a total of 53,907 patients were included. Six observational studies and one randomized controlled trial were selected. Three studies used the same registry but were not included in the same analysis. DAPT was associated with a significant decrease in the risk of major amputation in both overall analysis (risk ratio [RR], 0.82; 95% confidence interval [CI], 0.75-0.89; P < .001; I2 = 0%) and endovascular subanalysis (RR, 0.83; 95% CI, 0.73-0.93; P = .002; I2 = 0%). However, DAPT was associated with an increased risk of major adverse limb events (RR, 1.10; 95% CI, 1.03-1.18; P = .007) and any vessel reintervention (RR, 1.07; 95% CI, 1.03-1.10; P < .001; I2 = 0%). No significant differences were observed between DAPT and MAPT in either the overall or endovascular analyses regarding mortality, major bleeding, target lesion reintervention, or amputation-free survival. CONCLUSIONS: These findings suggest that using DAPT in patients with critical limb-threatening ischemia has the potential to decrease the number of amputations when compared with MAPT. However, DAPT may increase the likelihood of major adverse events and the need for any vessel reintervention. No statistically significant differences were identified between DAPT and MAPT for the outcomes of mortality, survival, major bleeding, or target lesion reintervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. de Albuquerque Farias Camarotti T, Camarotti MT, Donato KO, et al. Dual antiplatelet therapy versus monotherapy after surgical intervention for chronic limb-threatening ischemia: Systematic review and meta-analysis with endovascular subanalysis. J Vasc Surg. 2025. PMID: 40774361. doi:10.1016/j.jvs.2025.07.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。